Marie Christin Hasselluhn

Has grant

Associate Research Scientist

Columbia University Irving Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Combination CAF/myeloid targeting for pancreatic cancer therapy

Open Date: 2020-01-01

Close Date:

Articles (35)

Year:

2025

Pancreatic ductal adenocarcinoma is a deadly disease and is projected to become the second leading cause of cancer-related death by 2030. A major hallmark is the exuberant host response comprising the tumor microenvironment, of which, cancer-associated fibroblasts (CAF) are a prevalent component. Despite the gains in understanding of their heterogeneity and functionality from CAF studies in recent years, there are many unanswered questions surrounding this diverse population of cells. Here, we summarize the views of several experts in the field, focusing on the current understanding of CAFs and challenges to address.

Year:

2024

Year:

2024

Pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for effective treatment, with systemic chemotherapy often proving inadequate due to poor drug delivery and the tumor’s immunosuppressive microenvironment. Engineered bacteria present a novel approach to target PDAC, leveraging their ability to colonize tumors and deliver therapeutic payloads. Here, we engineered probiotic Escherichia coli Nissle 1917 (EcN) to produce the pore-forming Theta toxin (Nis-Theta) and evaluated its efficacy in a preclinical model of PDAC. Probiotic administration resulted in selective colonization of tumor tissue, leading to improved overall survival compared to standard chemotherapy. Moreover, this strain exhibited cytotoxic effects on both primary and distant tumor lesions while sparing normal tissues. Importantly, treatment also modulated the tumor microenvironment by increasing anti-tumor immune cell populations and reducing immunosuppressive markers. These findings demonstrate the potential of engineered probiotic bacteria as a safe and effective therapeutic approach for PDAC, offering promise for improved patient outcomes.

Year:

2024

Epithelial network. Regulatory network for PDAC-associated epithelial cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).

Year:

2024

Endothelial network. Regulatory network for PDAC-associated endothelial cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).

Year:

2024

Supplementary Table 1: Raw read counts per gene for bulk RNA-seq IPI-926 intervention study. Raw read counts of matching biopsy (Bx) and necropsy (Nx) bulk RNA-seq samples after two days of treatment with vehicle or IPI-926. Supplementary Table 2: Digestion buffer for single cell preparation. List of reagents optimized for single cell digestion of KPC-derived tumors. Supplementary Table 3: Single Cell RNA-seq Quality Control. Overview of KPC-derived scRNA-seq samples, containing treatment information (vehicle or IPI-926; n=3 each), sequencing depth, detected genes, and detection of mitochondrial genes (MT%). Supplementary Table 4: Network sizes in murine scRNA-seq data. Number of regulatory proteins for which regulons were generated in each network type, in each cell type, from KPC mouse pancreatic tumors.

Year:

2024

Myeloid network. Regulatory network for PDAC-associated myeloid cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).

Year:

2024

Lymphoid network. Regulatory network for PDAC-associated lymphoid cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).

Year:

2024

Myeloid network. Regulatory network for PDAC-associated myeloid cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (7)

Hanina Hibshoosh

Professor of pathology at CUIMC

Columbia University

UNITED STATES
View details

Tal Danino

Columbia University

UNITED STATES
View details

Alexander Muir

Assistant professor

University of Chicago

UNITED STATES
View details

Débora Barbosa Vendramini-Costa

Associate Professor Research

Michigan State University

UNITED STATES
View details

Kenneth Olive

Assistant Dean of Graduate Curricula and Associate Professor of Medicine

Columbia University Irving Medical Center

UNITED STATES
View details

Andrea Califano

Columbia University Irving Medical Center

UNITED STATES
View details

Tetsuhiro Harimoto

Dana-Farber Cancer Institute

UNITED STATES
View details